Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MME | P08473 | 3/20 | 0.31 |
| ▸ | PER2 | O15055 | 1/20 | 0.30 |
| ▸ | CRY1 | Q16526 | 1/20 | 0.30 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3068513 | 0.76 | ALDH1A1 (0.38) | KMT2APER2CRY1CRY2CYP2D6 | |
| SCHEMBL1861130 | 0.75 | KDM4E (0.37) | TGFBR1MMECYP2D6CYP2C19 | |
| SCHEMBL1861129 | 0.75 | KDM4E (0.37) | TGFBR1MMECYP2D6CYP2C19 | |
| SCHEMBL2840047 | 0.73 | — | — | |
| SCHEMBL27638949 | 0.73 | PLA2G2C (0.40) | TGFBR1KMT2AMMECYP2C19 | |
| SCHEMBL5548951 | 0.73 | PLA2G2C (0.40) | TGFBR1KMT2AMMECYP2C19 | |
| SCHEMBL14844611 | 0.73 | CYP2D6 (0.46) | TGFBR1CYP2D6CYP2C19 | |
| SCHEMBL3544030 | 0.73 | CYP2D6 (0.46) | TGFBR1CYP2D6CYP2C19 | |
| SCHEMBL18983111 | 0.73 | CYP2D6 (0.46) | TGFBR1CYP2D6CYP2C19 | |
| SCHEMBL5112339 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190000832-A1 | TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF | Selder Pharma Inc. (US) | 2019-01-03 | — | — | US | disclosed |
| US-10016410-B2 | Tetrahydroisoquinolin-1-one derivative or salt thereof | SELDAR PHARMA INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20170189390-A1 | TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF | SELDAR PHARMA INC. (US) | 2017-07-06 | — | — | US | disclosed |
| US-9526719-B2 | Tetrahydroisoquinolin-1-one derivative or salt thereof | SELDAR PHARMA INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-20150359787-A1 | TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF | SELDAR PHARMA INC. (US) | 2015-12-17 | — | — | US | disclosed |
| EP-2149561-B1 | TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF | SELDAR PHARMA INC (US) | 2015-09-09 | — | — | EP | disclosed |
| US-20140058100-A1 | TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF | SELDAR PHARMA INC. (US) | 2014-02-27 | — | — | US | disclosed |
| EP-2149561-A1 | TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2010-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170189390-A1 | TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF | BRS3, BDKRB2, NTSR2 | TGFBR1 1709/4885KMT2A 1990/4885MME 1822/4885 |
| US-20150359787-A1 | TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF | BRS3, BDKRB2, NTSR2 | TGFBR1 1709/4885KMT2A 1990/4885MME 1822/4885 |
| US-10016410-B2 | Tetrahydroisoquinolin-1-one derivative or salt thereof | BRS3, BDKRB2, NTSR2 | TGFBR1 1709/4885KMT2A 1990/4885MME 1822/4885 |
| US-20140058100-A1 | TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF | BRS3, BDKRB2, NTSR2 | TGFBR1 1709/4885KMT2A 1990/4885MME 1822/4885 |
| US-20190000832-A1 | TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF | BRS3, BDKRB2, NTSR2 | TGFBR1 1709/4885KMT2A 1990/4885MME 1822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.